Oxford kicks off HIV vaccine trial

Vaccine

The HIV-CORE 0052 trial will assess the safety, tolerability, and immunogenicity of the HIVconsvX vaccine

Please register to continue reading this content

Guidelines is completely free for all UK-based healthcare professionals